Xenon as an anesthetic agent

AANA Journal

Volumn 78, Issue 5, 2010, Pages 387-392

  Jordan, Bryan D ^a   Wright, Elizabeth Laura ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

General anesthesia; Inhalational agent; Nitrous oxide; Noble gas; Xenon

Indexed keywords

ANESTHETIC AGENT; DESFLURANE; INERT GAS; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE; NITROUS OXIDE; OPIATE RECEPTOR; XENON;

ANALGESIC ACTIVITY; ANESTHESIA; ANTINOCICEPTION; BRAIN BLOOD FLOW; BRAIN REGION; DRUG ANTAGONISM; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; HEMODYNAMICS; HUMAN; NEUROPROTECTION; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; SPINAL CORD DORSAL HORN;

ANESTHESIA, GENERAL; ANESTHETICS, INHALATION; CARDIOVASCULAR SYSTEM; DRUG COSTS; HUMANS; NEUROPROTECTIVE AGENTS; NITROUS OXIDE; NOBLE GASES; XENON;

EID: 78049280645     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Aziz T. Xenon in anesthesia. Int Anesthesiol Clin. 2001;39(2):1-14.
2. Joyce J. Xenon: anesthesia for the 21st century. AANA J. 2000;68(3):259-264.
3. Eger E. Age, minimum alveolar anesthetic concentration, and minimum alveolar anesthetic concentration-awake. Anesth Analg. 2001;93(4):947-953. (Pubitemid 32905984)
4. Grasshoff C, Rudolph U, Antkowiak B. Molecular and systemic mechanisms of general anaesthesia: the "multi-site and multiple mechanisms" concept. Curr Opin Anaesthesiol. 2005;18(4):386-391.
5. Franks N. Molecular targets underlying general anesthesia. Br J Pharmacol. 2006;147(suppl 1):S72-S81.
6. Sonner J, Antognini J, Dutton R, et al. Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Analg. 2003;97(3):718-740. (Pubitemid 37046437)
7. Heimburg T, Jackson A. The thermodynamics of general anesthesia. Biophys J. 2007;92(9):3159-3165.
8. Morgan G, Mikhail M, Murray M. Inhalational anesthetics. Clinical Anesthesiology. 4th ed. New York, NY: McGraw-Hill; 2006:127-145.
9. Mapleson W. Effect of age on MAC in humans: a meta-analysis. Br J Anaesth. 1996;76(2):179-185. (Pubitemid 26043445)
10. Lide D. CRC Handbook of Chemistry and Physics. 86th ed. Boca Raton, FL: Taylor & Francis Group; 2005.
11. Preckel B, Schlack W. Inert gases as the future inhalational anaesthetics? Best Pract Res Clin Anaesthesiol. 2005;19(3):365-379.
12. Hanne P, Marx T, Musati S, Santo M, Suwa K, Morita S. Xenon: uptake and costs. Int Anesthesiol Clin. 2001;39(2):43-61.
13. Sanders R, Franks N, Maze M. Xenon: no stranger to anaesthesia. Br J Anaesth. 2003;91(5):709-717.
14. Sanders R, Ma D, Maze M. Xenon: elemental anaesthesia in clinical practice. Br Med Bull. February 2005;71:115-135.
15. Cullen S, Gross E. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science. 1951;113(2942):580-582.
16. Eger EI Jr, Brandstater B, Saidman LJ, Regan MJ, Severinghaus JW, Munson ES. Equipotent alveolar concentrations of methoxyflurane, halothane, diethyl ether, fluroxene, cyclopropane, xenon and nitrous oxide in the dog. Anesthesiology. 1965;26(6):771-777.
17. Petersen-Felix S, Luginbühl M, Schnider T, Curatolo M, Arendt-Nielsen L, Zbinden A. Comparison of the analgesic potency of xenon and nitrous oxide in humans evaluated by experimental pain. Br J Anaesth. 1998;81(5):742-747.
18. Steward A, Allott P, Cowles A, Mapleson W. Solubility coefficients for inhaled anaesthetics for water, oil and biological media. Br J Anaesth. 1973;45(3):282-293.
19. Goto T, Suwa K, Uezono S, Ichinose F, Uchiyama M, Morita S. The blood-gas partition coefficient of xenon may be lower than generally accepted. Br J Anaesth. 1998;80(2):255-256.
20. Barker E. The xenon CT: a new neuro tool. RN. 1998;61(2):22-25.
21. Salmi E, Laitio R, Aalto S, et al. Xenon does not affect gamma-aminobutyric acid type A receptor binding in humans. Anesth Analg. 2008;106(1):129-134.
22. Jevtović-Todorović V, Todorović S, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4(4):460-463.
23. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983;79(2):565-575.
24. Miyazaki Y, Adachi T, Utsumi J, Shichino T, Segawa H. Xenon has greater inhibitory effects on spinal dorsal horn neurons than nitrous oxide in spinal cord transected cats. Anesth Analg. 1999;88(4):893-897.
25. Nakata Y, Goto T, Ishiguro Y, et al. Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans. Anesthesiology. 2001;91(4):611-614.
26. Goto T, Nakata Y, Ishiguro Y, Niimi Y, Suwa K, Morita S. Minimum alveolar concentration-awake of xenon alone and in combination with isoflurane or sevoflurane. Anesthesiology. 2000;93(5):1118-1193.
27. Goto T, Saito H, Shinkai M, Nakata Y, Ichinose F, Morita S. Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. Anesthesiology. 1997;86(6):1273-1278.
28. Dingley J, King R, Hughes L, et al. Exploration of xenon as a potential cardiostable sedative: a comparison with propofol after cardiac surgery. Anaesthesia. 2001;56(9):829-835.
29. Emmanouil DE, Quock RM. Advances in understanding the actions of nitrous oxide. Anesth Prog. 2007;51(1):9-18.
30. Yagi M, Mashimo T, Kawaguchi T, Yoshiya I. Analgesic and hypnotic effects of subanaesthetic concentrations of xenon in human volunteers: comparison with nitrous oxide. Br J Anaesth. 1995;74(6):670-673.
31. Lachmann B, Armbruster S, Schairer W, et al. Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet. 1990;335(8703):1413- 1415.
32. Barakat A, Schreiber M, Flaschar J, Georgieff M, Schraag S. The effective concentration 50 (EC50) for propofol with 70% xenon versus 70% nitrous oxide. Anesth Analg. 2008;106(3):823-829.
33. Ishiguro Y. Cardiovascular effects of xenon. Int Anesthesiol Clin. 2001;39(1):77-84.
34. Boomsma F, Rupreht J, Man in 't Veld AJ, de Jong FM, Dzoljic M, Lachmann B. Haemodynamic and neurohumoral effects of xenon anaesthesia: a comparison with nitrous oxide. Anaesthesia. 1990;45(4):273-278.
35. Stowe D, Rehmert G, Kwok W, Weigt H, Georgieff M, Bosnjak Z. Xenon does not alter cardiac function or major cation currents in isolated guinea pig hearts or myocytes. Anesthesiology. 2000;92(2):516-522.
36. Hettrick D, Pagel P, Kersten J, et al. Cardiovascular effects of xenon in isoflurane-anesthetized dogs with dilated cardiomyopathy. Anesthesiology. 1998;89(5):1166-1173. (Pubitemid 28516541)
37. Marx T, Froeba G, Wagner D, Baeder S, Goertz A, Georgieff M. Effects on haemodynamics and catecholamine release of xenon anaesthesia compared with total i.v. anaesthesia in the pig. Br J Anaesth. 1997;78(3):326-327.
38. Hardingham G, Bading H. The yin and yang of NMDA receptor signaling. Trends Neurosci. 2003;26(7):81-89.
39. Ma D, Wilhelm S, Maze M, Franks N. Neuroprotective and neurotoxic properties of the "inert" gas, xenon. Br J Anaesth. 2002;89(5):739-746.
40. Ma D, Yang H, Lynch J, Franks NP, Maze M, Grocott HP. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology. 2003;98(3):690-698.
41. 2O enhances ketamine-induced c-fos expression in the rat posterior cingulate and retrosplenial cortices. Anesth Analg. 2001;92(2):362-368.
42. Rex S, Schaefer W, Meyer P, et al. Positron emission tomography study of regional cerebral metabolism during general anesthesia with xenon in humans. Anesthesiology. 2006;105(5):936-943.
43. Rex S, Meyer PT, Baumert JH, et al. Positron emission tomography study of regional cerebral blood flow and flow-metabolism coupling during general anaesthesia with xenon in humans. Br J Anaesth. 2008;100(5):667-675.
44. Laitio R, Kaisti K, Låangsjö J, et al. Effects of xenon anesthesia on cerebral blood flow in humans: a positron emission tomography study. Anesthesiology. 2007;106(6):1128-1133.
45. Rossaint R, Reyle-Hahn M, Schulte J, et al. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology. 2003;98(1):6-13.
46. Nakata Y, Goto T, Niimi Y, Morita S. Cost analysis of xenon anesthesia: a comparison with nitrous oxide-isoflurane and nitrous oxide-sevoflurane anesthesia. J Clin Anesth. 1999;11(6):477-481.
47. Dingley J, Mason R. A cryogenic machine for selective recovery of xenon from breathing system waste gases. Anesth Analg. 2007;105(5):1312-1318.
48. Reinelt H, Marx T, Kotzerke J, et al. Hepatic function during xenon anesthesia in pigs. Acta Anaesthesiol Scand. 2002;46(6):713-716.
49. Baur C, Klingler W, Jurkat-Rott K, et al. Xenon does not induce contracture in human malignant hyperthermia muscle. Br J Anaesth. 2000;85(5):712-716.
50. Zhang P, Ohara A, Mashimo T, Imanaka H, Uchiyama A, Yoshiya I. Pulmonary resistance in dogs: a comparison of xenon with nitrous oxide. Can J Anaesth. 1995;42(6):547-553.